- Home
- STTK vs TPCS Comparison
STTK vs TPCS Comparison
Compare STTK & TPCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- TPCS
- Stock Information
- Founded
- STTK 2016
- TPCS 1956
- Country
- STTK United States
- TPCS United States
- Employees
- STTK N/A
- TPCS N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- TPCS Metal Fabrications
- Sector
- STTK Health Care
- TPCS Industrials
- Exchange
- STTK Nasdaq
- TPCS Nasdaq
- Market Cap
- STTK 37.6M
- TPCS 42.6M
- IPO Year
- STTK 2020
- TPCS N/A
- Fundamental
- Price
- STTK $1.00
- TPCS $3.56
- Analyst Decision
- STTK Hold
- TPCS
- Analyst Count
- STTK 4
- TPCS 0
- Target Price
- STTK $3.00
- TPCS N/A
- AVG Volume (30 Days)
- STTK 112.0K
- TPCS 26.7K
- Earning Date
- STTK 07-31-2025
- TPCS 04-08-2025
- Dividend Yield
- STTK N/A
- TPCS N/A
- EPS Growth
- STTK N/A
- TPCS N/A
- EPS
- STTK N/A
- TPCS N/A
- Revenue
- STTK $4,606,000.00
- TPCS $33,154,058.00
- Revenue This Year
- STTK N/A
- TPCS N/A
- Revenue Next Year
- STTK N/A
- TPCS N/A
- P/E Ratio
- STTK N/A
- TPCS N/A
- Revenue Growth
- STTK 69.65
- TPCS 8.71
- 52 Week Low
- STTK $0.69
- TPCS $2.05
- 52 Week High
- STTK $4.99
- TPCS $4.42
- Technical
- Relative Strength Index (RSI)
- STTK 47.54
- TPCS 52.13
- Support Level
- STTK $0.91
- TPCS $3.52
- Resistance Level
- STTK $1.14
- TPCS $3.88
- Average True Range (ATR)
- STTK 0.08
- TPCS 0.23
- MACD
- STTK -0.01
- TPCS -0.01
- Stochastic Oscillator
- STTK 28.35
- TPCS 51.25
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.
About TPCS TechPrecision Corporation Common stock
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components.